Skip to main content
. 2022 May 18;14(10):2486. doi: 10.3390/cancers14102486

Figure 13.

Figure 13

Gemcitabine increases IL-6 expression in the surviving malignant cells, which in turn inhibits gemcitabine’s cytotoxicity through the production/secretion of IL-6.